A Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Protocol
11-003
Full Title
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide (CALGB 30610/RTOG 0538)
Phase
III
Purpose

The standard therapy for limited small cell lung cancer is chemotherapy with cisplatin and etoposide every three weeks, plus radiation therapy twice a day for three weeks. In this study, researchers want to study two other chemoradiation regimens with the standard therapy to compare their effectiveness and their side effects.

Patients will be randomly assigned to receive the standard treatment regimen or one of two investigational regimens. In one investigational regimen, radiation therapy is given once a day for seven weeks. In the second investigational regimen, patients receive radiation once a day for 16 days of treatment (about three weeks), followed by radiation twice a day for the remaining 9 days of treatment (about two weeks), for a total of five weeks. Patients in all three study groups will receive cisplatin and etoposide every three weeks.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have limited small cell lung cancer.
  • Patients whose cancer has been completely removed with surgery may not participate.
  • Patients may not have had prior chemotherapy or radiation therapy for small cell lung cancer.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Andreas Rimner at 212-639-6025.

Disease(s)
Lung Cancer
Lung Cancer, Small Cell
Lung Cancer, Small Cell: Other
Related Diseases